ABBV-744
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ABBV-744, covering 2025-07-16 to 2025-07-16. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis [Phase 1]